Member Info for Dystopian

Jurrian Dekkers was appointed in December 2025, the process would have started months back in the year. He undoubtedly would have been given a very upbeat version of the company’s future. Once in post he obviously got the full picture and probably felt somewhat aggrieved – he had the brass neck i.e. didn’t care what his colleagues thought- to sell out and made a perfectly legal decision. Ultimately though , Faron will get enough cash to continue with the trial so the horizon moves a bit more . IMO the fact big pharma does not at this point think its worth buying in in any form just adds more uncertainly , hence the drop.

In my last post, when Dekkers sold, I rather jokingly said that the only rational for selling was that he expected to be buyingthem back for £ 0.30 in the near future. Unfortunately this well may come to pass. As always take the long view, working in Biotech/ biopharma you can make a good living for years getting the investors to fund your lifestyle...

The only rational for this type of behaviour ( and I sincerely hope I am totally wrong ! ) is that he expects to be buying them back at £ 0.30 p a pop in the near future in the expectation that eventually it will all come good!

Howard , there’s no stopping a good man (?) like JuniorBLT-Zengah. Take a look at this recent posting 16.12.2025

“Dekkers is a world class CFO, pulling off moves such as the Acerta deal, a $7bn option to acquire with 4bn upfront from Astra Zeneca and a further $3 bn following approvals; he will be able to raise cash with strategic investors in weeks. “

This deal was instigated in 2016 – from the Acerta website

“ In February 2016, AstraZeneca made an investment in Acerta Pharma for 55% ownership, driven by the opportunity to build out its haematology pipeline. In 2021, AstraZeneca exercised the option to purchase the remainder of Acerta Pharma and completed the acquisition of Acerta Pharma.”

In 2016 Mr Dekkers was working for the DaVita Medical group. He had nothing to do with the Acerta deal at the time or its 7 Billion valuation. He was in place Acerta when the option to take over was exercised by AZ but to say he was the man who made the deal happen is as usual, BS. The option to purchase was based on the ongoing scientific progress.

I’m not denigrating Mr Dekkkers in any way, he is no doubt a competent CFO doing a good job, but to suggest he is some form of CFO superstar is ludicrous. He was brought in because Wichmann is retiring and Faron have got the succession in place with a decent candidate.

As for now Faron have a decent amount of breathing space due to the recent funding release, plus as was pointed out by Its. , Finnish investors have added plenty of shares over the last 12 months so watch this space.

This patent was filed Jan. 25, 2021.

Howard, I put this JRjnr posters history through a couple of AI apps. It seems that JNjnr, Esther ,( long dead ) Tommy ( long dead ) Zengah, Bmhltd and some chap called Porky9 are all the same person ! ( Apologies Porky9 if you are not associated with these characters .) There were also some outliers but I’m not too sure about these. It also questioned whether English was their first language ? It’s no surprise you received a torrent of abuse when you asked a pretty straight question, demanding a pretty straight answer!

I guess you could block him/her/it, but personally I find these deranged rampers/day traders hilarious and look forward to their projections.

Seriously I don’t think there will be a buyout anytime soon as I can’t see the board recommending anything below £ 10 PS and it’s unlikely BP will pay a 5x premium right now – Fierce Biotech are a good resource for checking out just what premiums have been applied to buyouts over the last year or so.

I believe a partnership is much more likely- the crunch is that Faron have to get Phase 3 going asap, if not the cash will burn up putting them is a poor negotiating position. Hopefully they will get a decent one soon, based on the data so far. But again going on past deals this could only put the price up to maybe £ 6 or so – this means quids in for some, but not me- that’s just break even ( actually worse) after some averaging down earlier this year. The riskiest scenario would be to start phase 111 with what they have in the pot right now. If no funding comes forward in the right timeframe they either curtail the trial and really damage their reputation with the trial centres ( trial centres do not like not getting paid, nor do the CROs who actually do the field work) or accept a poor bail out deal. Either way for me I think its 2 years before I make much out of this, but for those who got in at a low point Christmas might well come early. All IMHO of course.

BMH,

Here is your posting from December 2024, I asked you to qualify it, your answer was " Sure ", so far you haven't. Could you please go ahead an explain how your research brought you to this conclusion .

"Juho clearly stated we are in a dynamic, fast changing scenario wrt fundraising and what’s required. Clearly talking to multiples partners & a formal bid becomes inevitable.

At which point it will have to be disclosed, and will likely be in the billions given 2.7B in revenues commencing in the next few months.

The FDA will be ethically compelled to approve this treatment prior to P3, one way or another.

Likely some games along the way but I personally feel we are very close to a £3-5Bn (28.50-47.50 p/s) offer for the whole company, given the M&A landscape and Farons compelling data.

Sounds insane but I don’t see how it goes for less….

GLA and hold TIGHT!!!!!! "

BmhltdLtd . The fact that a Top-tier bank has been appointed as you state, is very interesting news to all investors- do you mind informing us who this is ?

The fact board members have shelled out for substantial numbers of shares, outside of a stock release , means more to me than any amount of speculation or conjecture. Its the best recommendation regards the future trajectory of the stock price.

For what it's worth I believe this is actually a good time to invest. Come what may the likelyhood of getting a partner in the next few months is as good as its ever been. I've held off for a long time but I've taken the plunge and decided to average down.

Longy00000, Apologies for the late reply.

Thanks for this opinion, I guess there's certainly a valid case for the rerate happening in the next year- there a lot of factors bearing on this- sentiment often has a large part to play- if investors really think it's the next frontier in immunotherapy then they'll buy in . There's certainly some positive ground swell opinion at work here, as shown by the SP increase. Personally one of the events which I tend to place most faith in ( albeit misplaced at times) is when are the directors buying in. Buying in when there's a share release is one matter- essentially directors have to take up the options otherwise it would demonstrare a lack of faith in your own company. However if directors buy in at other times - and of course as PIs we legally have access to this info then its another matter.For example Matti Karnoven Chief Medical officer - at the time 2017 - made a series of significant purchases when it looked like Traumakine was a goer, as did Jonathan Knowles ( Scientific Board ) in September of 2017 - a massive amount. I 'm sure this helped push the SP to £ 8 or so. The fact Traumakine failed another matter- the Directors obviously were convinced of success , so if I see this sort of activety in the next few months I'm confident the SP will keep on going up. The big question is when to take profits. I didn't so I'm sitting here waiting for it to get back to £ 7.00 to get even. Such is life.

RE my post regarding revenue streams, this was posted in April 2024 ie a year ago , so are looking at 3-4 years now.

What’s the average time to bring a drug to market?

According to industry group PhRMA, it takes 10-15 years on average to develop one new medicine from initial discovery through regulatory approval.

Other sources corroborate this number. Biotechnology Innovation Organization (BIO), another industry group, analyzed 9,704 clinical development programs over the course of a decade from January 2011 to November 2020. They found that, on average, it took 10.5 years for a drug to get from Phase I to regulatory approval. There is endless data on this subject - a quick google search will do .

Here is a link, just

https://lifesciences.n-side.com/blog/what-is-the-average-time-to-bring-a-drug-to-market-in-2022

one of many similar - basically it takes about 3.3 years to get through phase 111 on average ,then another 1.3 or so get get your asset to market. I accept that an accelerated approval can reduce the time, but its all dependent on trial results. Therefore I'm sticking with my original estimate which now pans out at 3-4 years .

Looking at individual stages of the process, the averages were 2.3 years for Phase I, 3.6 years for Phase II, 3.3 years for Phase III, and 1.3 years between Phase III and regulatory approval.

BMHltd'

There is some confusion going on here. The trial in the study I posted the link for was a phase 1B, published in 2020. Here is a quote from the lead investigator

In this ongoing study, treatment with magrolimab and azacitidine continues to achieve promising, durable responses in patients with AML who are ineligible for first-line chemotherapy,” said David Sallman, MD, H. Lee Moffitt Cancer Center and Research Institute, an investigator for the clinical trial. “These findings are especially encouraging for patients with TP53 mutations, which are associated with poor outcomes and limited response to existing treatment options.”

In the study, 64 patients were treated with magrolimab plus azacitidine, including 47 patients with the TP53 mutation, a treatment-refractory and poor-prognosis population. As of November 2020, 63% (n=27/43) of patients evaluable for efficacy achieved an objective response per European LeukemiaNet 2017 criteria, 42% (n=18/43) achieved a complete remission (CR), and 12% (n=5/43) achieved a CR with an incomplete count recovery (CRi). The median duration of response (DOR) was 9.6 months (range: 0.03+ to 18.7 months) and the median time to response was 1.95 months (range: 0.95 to 5.6 months).

The point I am ,making is the phase 1 data was very encouraging , where as the drug development was stopped in 2024 during phase 111. This is why drugs go through enlarged phase 111 trials to ensure any unforeseen problems are discovered prior to licensing.

My last post re this subject.

Here is a post from Dec 2024 from you . Please explain how the FDA will be ethically compelled to approve BEX, before phase 111. ? How do you get to £ 2.7 B revenue commencing in the next few months ? . How do we get to a £ 27- 48 per share buyout deal ( very close in your words ) ?

Juho clearly stated we are in a dynamic, fast changing scenario wrt fundraising and what’s required. Clearly talking to multiples partners & a formal bid becomes inevitable.

At which point it will have to be disclosed, and will likely be in the billions given 2.7B in revenues commencing in the next few months.

The FDA will be ethically compelled to approve this treatment prior to P3, one way or another.

Likely some games along the way but I personally feel we are very close to a £3-5Bn (28.50-47.50 p/s) offer for the whole company, given the M&A landscape and Farons compelling data.

Sounds insane but I don’t see how it goes for less….

GLA and hold TIGHT!!!!!!

bmhltd . may i inform you that this forum is a discussion opportunity - the good, the bad, the totally nuts, - it is not a forum for ****ging off other posters who's opinions do not align with your own, nor is it meant to be a forum for posting endless fake news or total misreprentation of published and peer reviewed data. you are entitled to say what you want on this forum , but if you cannot accept some constructive criticism and or debate about your posts i suggest you leave . anyone can say what they want about my posts - but i take in all in good heart ( within reason ! ). i should also point out i have spent my entire working life in life science arena , so i'd like to think my posts all add to the general pot of inormation re faron.

Hope this helps.......

Preliminary median overall survival (OS) for TP53-wild-type patients (n=16) was 18.9 months (95% CI: 4.34, NE) and for TP53-mutant patients (n=47) was 12.9 months (95% CI: 8.21, 17.28).

re missing the point - gilead announced they would accquire forty seven in march 2020. gilead then published data in dec 2020 showing that magrolimab showed excellent survival data- hence they went ahead with fda approval to phase 111. therefore no monumental **** up was made at this point. the point i am making is that until a much larger phase 111 takes place it is unwise to make overly opitimistic projections. i only invest having applied the most hard headed of decisions based on the best available information- big pharma also work this way.

https://www.gilead.com/news/news-details/2020/magrolimab-demonstrates-clinical-responses-in-ongoing-phase-1b-trial-of-previously-untreated-acute-myeloid-leukemia-patients

https://www.gilead.com/news/news-details/2020/gilead-to-acquire-forty-seven-for-49-billion

gilead published data in dec 2020

Its worth pointing out that Gilead bought Forty Seven to get hold of Magrolimab , which was then pulled by the FDA in phase 111- Gilead got a rather bloody nose from this episode. It just illustrates the fact that immuno-oncology is " difficult" science with a lot of uncertainties baked in. Failures such as this amke big pharma even more cautious about shelling out big money. Personally I am cautiously opitimistic about the future of Bex but there is a lot of work to do to pin down exactly which patients will benefit most and under what conditions. From what I have seen over a long period, the positives are that a partnership or buyout is impossible to predict , it could come tomorrow or in 3 years time- it certainly makes life interesting .

Hopefully this report will put to bed all the ludicrous projections re absurd share prices just around the corner (£ 100 a pop anyone ? ) and hopes that Bex will get a license in double quick time. Its a very measured piece of work , but nothing anyone who has done their research doesn't know already. The share price has to get to £ 7 before I'm out of the hole but I'm prepared to wait . As always it's all down to the biology , so roll on April - the rest is mostly conjecture not matter what spin is applied.

How long before E Musk calls foul ? Tesla SP is taking a battering . Eventually there will be a titanic fall out.